🔎 Trials Near Me

Akèy › Kansè kolorektal › Maryland

Etid klinik pou Kansè kolorektal nan Maryland

47 etid pou Kansè kolorektal ap chèche patisipan nan sit nan Maryland.

Vil nan Maryland

Tèks ofisyèl etid la (Anglè)

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Walter Reed National Military Medical Center, Bethesda
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Oct 5, 2026 · NCT06995898

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

  • National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 2 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT01915225

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 72 · Tout sèks · Mizajou Oct 2, 2026 · NCT01174121

Evaluation for NCI Surgery Branch Clinical Research Protocols

  • National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT00001823

Family Communications After Genetic Testing

  • Sinai Hospital of Baltimore, Baltimore
  • Northwest Hospital Center, Randallstown
  • UM Saint Joseph Medical Center, Towson
  • ak 1 plis
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07143487

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • ak 10 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #14, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  • Greater Baltimore Medical Center, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07222800

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

  • National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2Mande peman pou patisipan yo
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT06149481

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  • MedStar Franklin Square Medical Center, Baltimore
  • Frederick Health Hospital - James M Stockman Cancer Institute, Frederick
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06750094

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  • MedStar Franklin Square Medical Center, Baltimore
  • Frederick Health Hospital - James M Stockman Cancer Institute, Frederick
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06662786

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  • Local Institution - 0262, Baltimore
  • Maryland Oncology Hematology - Silver Spring, Silver Spring
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07221357

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

  • National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 12 a 120 · Tout sèks · Mizajou Sep 23, 2026 · NCT04222413

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • United Theranostics, Glen Burnie
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213791

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06445062

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • Johns Hopkins, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07349537

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  • Saint Agnes Hospital, Baltimore
  • Cancer Center For Blood Disorders A Division of American Oncology Partners P.A, Bethesda
  • Sarah Cannon Research Institute Scri Oncology Partners, Brandywine
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07284849

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

  • United Theranostics, Glen Burnie
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07812805

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07147231

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

  • Clinical Study Site, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07228832

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

  • Research Site, Baltimore
Ap rekriteFaz 2
Laj 18 a 130 · Tout sèks · Mizajou Aug 18, 2026 · NCT06792695

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • National Institutes of Health, Bethesda
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

  • Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06411691

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

  • National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT05691491

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Maryland Oncology Hematology - Primary, Columbia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT04657068

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  • Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT06179160

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT06131840

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 21, 2026 · NCT07281768

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

  • Mercy Medical Center, Baltimore
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT06562543

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

  • Frederick Health Hospital, Frederick
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07327489

Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

  • Johns Hopkins University, Baltimore
Ap rekrite
Laj 21 ak plis · Tout sèks · Mizajou Jun 16, 2026 · NCT07337590

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

  • Maryland Oncology Hematology, Columbia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT07011576

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • Advanced Molecular Imaging and Therapy, Glen Burnie
  • United Theranostics - Chesapeake, Glen Burnie
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05283330

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  • Johns Hopkins University, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT06040541

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

  • Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 28, 2026 · NCT07223047

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • Johns Hopkins University, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT05379985

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.